STAT

Opinion: Invoking Bayh-Dole may be needed to get affordable Covid-19 treatments

It is shameful in 2020 to see some universities sign on to a coalition like Bayh-Dole 40 that actively aims to undermine a safeguard that exists to serve the public…

As the Covid-19 pandemic strains the capacity of the U.S. health care system, attention is being focused on developing new drugs and therapies to fight it.

Pharmaceutical company Moderna, for example, began clinical trials in Seattle for a new vaccine, providing welcome news to many. But what few Americans realize is just how much of their taxpayer dollars went into the development of these drugs long before Covid-19 emerged.

The Defense Research Advanced Projects Agency (DARPA), a part of the Department of Defense, has tens of millions of dollars into Moderna and other biotechnology companies since 2011. The National Institutes of.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks